Last edition
News about " injectable Ozempic"
Eli Lilly Reports Phase 3 Results for Retatrutide Against Ozempic in Type 2 Diabetes
Eli Lilly has reported positive Phase 3 results for investigational retatrutide, which demonstrated greater reductions in A1C and body weight than Ozempic 2 mg in adults with type 2 diabetes. Retatrutide is not approved for human use.
Injectable Ozempic | 29/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members